|

Sustained Release Oral Formulation for Treatment of Parkinson's Disease

RECRUITINGEarly 1Sponsored by University of Minnesota
Actively Recruiting
PhaseEarly 1
SponsorUniversity of Minnesota
Started2025-06-12
Est. completion2026-06-16
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT05471609

Summary

Achieving sustained blood levels of carbidopa/levodopa has been a challenge in the treatment of PD and although levodopa remains the most commonly used drug, motor fluctuations remain a major disability especially in advanced Parkinson's disease. The aim of this study is to determine the efficacy of a novel oral carbidopa-levodopa formulation in achieving a sustained blood level of levodopa and carbidopa in normal volunteers.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Normal healthy
* Are 18-65 years of age
* Are not currently taking medications regularly
* Able to fast 6 hours (water allowed)

Exclusion Criteria:

* Pregnancy
* Inability to fast

Conditions2

Healthy VolunteersParkinson's Disease

Locations1 site

University of Minnesota
Minneapolis, Minnesota, 55455
Research Coordinator507-339-4093umnstudies@gmail.com

Browse More Trials

Parkinson's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.